Terns Pharmaceuticals Amends 10-K to Detail Executive Compensation and Equity Plans Amidst Tender Offer
TERN has more than doubled off its 52-week low of $2.655.
Summary
Terns Pharmaceuticals filed an amended 10-K to include previously omitted executive compensation and equity plan details, offering insight into internal incentives during its ongoing tender offer and recent FDA breakthrough designation.
Key Events · Corporate Governance and Compliance · TERN
-
Executive Compensation Details
The filing provides full 2025 compensation for CEO Amy Burroughs ($4.59M total), CFO Andrew Gengos ($2.62M total), and CMO Emil Kuriakose ($2.36M total). It also outlines base salary increases and target bonus adjustments for 2026 for these executives.
-
CEO Market-Condition RSU Vesting
CEO Amy Burroughs' 150,000 market-condition RSUs fully vested as of December 31, 2025, due to achieving stock price thresholds of $15.00 and $20.00, with the underlying shares delivered in January 2026.
-
Significant Equity Plan Authorizations
The 2021 Incentive Award Plan increased by 5,616,234 shares and the 2021 Employee Stock Purchase Plan by 753,054 shares, effective January 1, 2026. This significantly expands the pool of shares available for future equity awards.
-
Updated Director Compensation
The company detailed increased annual cash retainers for non-employee directors and committee chairs/members for 2026. It also introduced an option for directors to receive equity in lieu of cash fees, subject to a $3.00 per share floor.
Analysis · TERN · Life Sciences
This 10-K/A provides crucial details on executive compensation, equity awards, and corporate governance for 2025, which were omitted from the original 10-K. The disclosure is particularly relevant as it comes amidst a pending tender offer by Merck and a recent FDA Breakthrough Therapy Designation for TERN-701. The vesting of market-condition RSUs for the CEO, triggered by specific stock price thresholds, highlights the company's strong performance leading up to these events. Additionally, the significant increase in shares authorized for equity compensation plans provides insight into potential future dilution and incentive structures during this pivotal period for the company.
At the time of this filing, TERN was trading at $52.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.1B. The 52-week trading range was $2.66 to $53.19. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.